Drug intelligence / Profile preview

TULY

Development stage: Phase 3
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

TULY is a pharmaceutical drug that contains rasburicase, a recombinant urate oxidase enzyme. It is developed for the prevention and treatment of malignancy-associated hyperuricemia, a condition characterized by elevated uric acid levels in the blood, often seen in patients with certain cancers like non-Hodgkin lymphoma or acute lymphoblastic leukemia. Rasburicase works by catalyzing the oxidation of uric acid into allantoin, a more soluble compound that is easily excreted by the kidneys, thereby reducing uric acid levels.

Brand names: TULY

Targets

UOX (Urate oxidase)

Beyond the preview

Go deeper on TULY.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TULY.

Explore the full profile